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Abstract 
Objective 
Depression is more common among individuals with chronic physical illness than in the 
general population. New treatments for severe and chronic inflammatory conditions which 
inhibit tumour necrosis factor alpha (TNFα), a pro-inflammatory cytokine, may be able to 
shed some light on the role of inflammatory mediators in depression. This systematic review 
and meta-analysis of randomised controlled trials determined the effects of TNFα inhibitor 
therapy on depression and anxiety in people with chronic physical illness.  
Methods 
Seven databases were searched from inception to January 2014: AMED, Central, Cochrane 
Database of Systematic Reviews, CINAHL, Embase, MEDLINE, and PsycINFO. Articles were 
screened for inclusion independently by two reviewers. Data extraction and appraisal were 
conducted by one reviewer and checked by a second. Random-effects meta-analyses were 
performed. 
Results 
Six randomised controlled trials (reported in seven articles) met eligibility criteria and were 
included in the final review. In total 2540 participants were enrolled across the trials, with 
participants presenting with rheumatoid arthritis (n=3 trials), psoriasis (n=2) or ankylosing 
spondylitis (n=1).  Meta-analyses, using standardised mean differences, showed evidence of 
small reductions in depression (-0.24; 95% CI -0.33 to -0.14; p <0.001), and anxiety (-0.17; 
95% CI -0.31 to -0.02; p=0.02).  
Conclusion 
TNFα inhibitor therapy reduces depression in people with chronic disease though the effects 
are small. Whilst this is consistent with inflammation contributing to the development of 
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depression, further studies investigating a more detailed timeline of changes in depression, 
inflammatory biomarkers and disease activity status are required. 
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1.0  Introduction 
Depression is two to three times more common in people with chronic physical illnesses 
than in the general population [1]. This is of particular concern as depression is associated 
with a range of adverse outcomes among people with chronic physical illnesses, including 
increased mortality [2-4], increased morbidity [5, 6], poorer health-related quality of life [7-
9], and increased healthcare use and costs [10, 11]. The causes of depression in the 
physically ill are complex and multifactorial. General risk factors, such as being female, 
having a family or personal history of depression, having markers of social deprivation, a 
lack of social support and marked psychosocial stresses are known to be predictive of 
depression [12]. Factors relating to the illness and its treatment also influence who develops 
depression, such as negative beliefs about illness [13], the presence of pain [12, 14], 
disability [15, 16] and unpleasant side-effects from treatment [17]. Understanding the 
causes of depression is of central importance in the management of individuals with chronic 
physical illnesses as it offers the opportunity to: i) identify those at greatest risk of additional 
illness burden due to depression, ii) identify those at risk of worse medical outcomes and iii) 
potentially reduce the risks of adverse medical outcomes, either by treating depression or 
increasing the intensity of medical management. 
 
Recently there has been growing interest in the roles of inflammation in contributing to the 
development of depression in people with physical illness [18, 19]. Depression is associated 
with an increase in biomarkers of inflammation, including c-reactive protein (CRP), 
interleukin 1 (IL-1), interleukin 6 (IL-6) and tumour necrosis factor alpha (TNFα), in clinical 
and community populations [20]  ADD HIMMERICK REF. Epidemiological studies have 
demonstrated that depression is predicted by higher levels of inflammatory mediators [21], 
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though such prospective associations have not been consistently observed with some 
finding depression predicting inflammation [22]. Controlled, experimental studies in healthy 
volunteers, in which inflammation is triggered by the acute administration of an endotoxin 
or attenuated vaccine, have demonstrated transient increases in the symptoms of 
depression associated with increases in IL-1 receptor antagonist (IL-1Ra), IL-6 and tumour 
necrosis factor alpha (TNFα) [23, 24]. Furthermore, administration of Interferon alpha, 
which greatly increases the level of inflammatory mediators, is associated with development 
of major depression in up to one third of patients [25], which is preventable in many by pre-
treatment with antidepressants [26, 27]. Whilst such observational studies and short-lived 
experimental studies provide evidence that inflammatory mechanisms contribute to the 
development of clinically significant depression in people with chronic physical illness, they 
fall short of proving the causal link. 
 
The recent development of pharmacological agents which specifically inhibit the 
inflammatory mediator TNFα, a pro-inflammatory cytokine, offer a new means of 
investigating the links between inflammation and depression [28]. Administration of TNFα 
inhibitors have resulted in a reduction of depression-like and anxiety-like symptoms in 
rodent models of depression (Camara 2015, Krugel 2013).  In clinical studies, TNFα inhibitors 
have been shown to improve outcomes in a high proportion of people with severe 
inflammatory disorders, who have failed to respond to other treatments. Indeed, TNFα 
inhibitors have also been shown to improve depressive symptoms among people with 
chronic inflammatory disorders [29], though this does not always appear to be the case [30]. 
More recently, Arisoy and colleagues [31] have shown that patients with ankylosing 
spondylitis who were treated with TNFα inhibitors reported a significant decrease in 
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depression which, importantly, was not associated with changes in markers of clinical 
disease activity. They, and others [32], have suggested that the improvements in depression 
but not markers of clinical disease activity, provides support for an inflammatory 
mechanism underpinning the development and maintenance of depression. Although the 
link between anxiety and inflammation has been much less studied, with recent findings of 
correlations between inflammatory markers and anxiety disorders and increased 
inflammatory activation in patients with anxiety disorders [33], anxiety was included as a 
secondary outcome of interest. 
 
The purpose of this systematic review therefore, was to determine whether TNFα inhibitor 
therapy in people with chronic physical illness reduces symptoms of depression and anxiety. 
Further, the review sought to explore the relationship between timing of change in 
depression and anxiety symptoms with change in either immunological or clinical status. 
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2.0  Methods 
The systematic review was conducted following the general principles published by the NHS 
Centre for Reviews and Dissemination [34] and has been reported in accordance with the 
PRISMA statement [35]. The protocol was registered with Prospero in September 2013 
(registration no. CRD 42013006068).  
2.1 Types of studies 
Only randomised controlled trials (RCTs) were considered eligible for the purposes of this 
review.  
2.2 Types of participants 
Individuals with a chronic physical illness undergoing treatment with a TNF-  inhibitor (this 
was likely to include, but was not exclusive to, conditions such as rheumatoid arthritis, 
psoriasis, crohn’s disease and ankylosing spondylitis). Studies which involved participants 
being treated for mental illness alone were not eligible. 
2.3 Types of interventions 
The intervention of interest was treatment with TNFα inhibitors, compared against usual 
care (treatment with a non TNFα inhibitor) or control. At the time of the review, the 
available TNFα inhibitors were Etanercept, Infliximab, Adalimumab, Certolizumab, and 
Golimumab.  Studies that simply compared two doses of TNFα inhibitors (with no control or 
usual care arm), or studies that assessed attenuation/escalation of TNFα inhibitors doses, in 
which both intervention arms received at least one dose of TNFα inhibitors were not 
considered eligible for inclusion. 
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2.4 Outcome measures 
The primary outcome of interest in this review was depression, assessed using a validated 
psychological measure, such as the Hospital Anxiety Depression Scale (HADS), and the Beck 
Depression Inventory (BDI).  A list of recognised measures of depression was agreed a priori 
(CD and RA). Self-reported measures of mental health related quality of life were not 
considered eligible. Secondary outcome measures of interest were anxiety, assessed with a 
recognised psychological measure, and measures of inflammatory and clinical disease status 
(only in relation to the timing of any changes in depression observed).  
2.5 Search Strategy 
The search strategy was developed by an information specialist (AB) in consultation with 
topic and methods experts (CD, BA, BW, JTC). The strategy used a combination of MeSH 
terms and free text terms, including terms for TNFα inhibitor or agonist, including the 
named drugs, and terms describing depression. An illustration of the exact search strategy 
used on MEDLINE can be seen in Figure 1. Seven databases were searched from inception to 
January 2014: AMED, Central, Cochrane Database of Systematic Reviews, CINAHL, Embase, 
MEDLINE, and PsycINFO. No date or language restrictions were used. We also searched 
ClinicalTrials.gov for recently completed and ongoing studies. Forward and backward 
citation chasing of each included article was conducted. Two reviewers (RA, with RW or AB) 
independently screened titles, abstracts and full texts using the eligibility criteria. 
Discrepancies were discussed and resolved by a third reviewer (RW or AB) where necessary.  
2.6 Risk of bias and study quality 
The methodological quality of each paper was assessed using the Cochrane ‘risk of bias’ tool 
[36]. The tool includes six key criteria against which potential risk of bias is judged: adequacy 
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of allocation sequence generation; adequacy of allocation concealment; blinding of 
participants, personnel or outcome assessors; completeness of outcome data; selectivity of 
outcome reporting, and other bias. In addition to the Cochrane risk of bias tool, four 
additional aspects of quality relating to reporting of eligibility criteria, similarity of baseline 
characteristics, compliance with intervention and data collection tool validity were assessed. 
Quality was assessed by one reviewer (RA, AB, or RW), with judgements checked by a 
second (RW, RA, or AB). Any discrepancies were discussed and resolved.  
2.7 Data collection 
Data on the study design, the setting, the population, the intervention, the outcomes and 
results, and risk of bias were collected using a standardised, piloted data extraction form. 
Data were extracted by one of two reviewers (RA, AB) and fully checked by another (RA or 
RW).  
2.8 Data analysis and synthesis 
Random effects meta-analyses were performed where we had sufficient data from RCTs for 
the effect of intervention on the outcome measures of depression and anxiety. Pooling was 
performed on the post intervention outcome measurement. As we used a random-effects 
model for the meta-analyses, the weightings for each study were determined not only by 
the size of each study included, but also by the estimate of between-study heterogeneity. 
All studies assessing depression, analysed change in outcome between baseline and post 
intervention. Across the six trials there were four different scales used to assess depression, 
and one study [37] only reported an adjusted standardised effect size between 
interventions and control, Therefore, in all but one study [37], unadjusted post-intervention 
summary data were used to calculate standardised effect sizes (ES) between groups. In the 
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case of the Tyring et al. study [38], where two different scales were used to measure the 
same outcome from the same population, we computed a single effect size as the mean of 
the effect sizes of the two scales and a variance that takes into account the correlation 
between the two scales [39].  As some have queried the interpretability of standardised 
effect sizes [40], we also performed a random effects meta-analysis on the non standardised 
mean differences data for studies in which the same depression scale only had been used. 
Data for this analysis is reported as the pooled mean difference with 95% confidence 
intervals. Anxiety was measured across the studies using the same assessment tool; 
however, as only the adjusted standardised effect size between groups was reported in one 
study [37], pooled effects are reported as standardised effects sizes with 95% confidence 
intervals. Heterogeneity across estimates was quantified using the I-squared statistic and 
tested using the Q-statistic [41]. Synthesised results are presented by outcome type. Effect 
sizes are expressed as small (0.2-0.5), moderate (0.5-0.8) and large (>0.8) [42]. Where 
pooling was not appropriate or possible, the findings have been summarised in narrative 
form. 
 
Data analysis was carried out using Stata [Stata Corporation. Stata Statistical Software. 
Release 12.1. College Station,TX, 2011] and Review Manager (RevMan) Version 5.2 software 
(http://ims.cochrane.org/revman). Synthesised results are presented by outcome type. 
Effect sizes are expressed as small (0.2-0.5), moderate (0.5-0.8) and large (>0.8) [42]. Where 
pooling was not appropriate or possible, the findings have been summarised in narrative 
form. 
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3.0 Results 
The electronic searches found a total of 1351 results, 360 of which were duplicates, leaving 
991 titles and abstracts to screen. After double screening of each one, 28 full texts were 
retrieved for closer examination. A total of seven articles (from six trials) were included in 
the final review, with two identified from forward and backward citation chasing. Reasons 
for exclusion at the full text stage can be seen in Figure 2. The ASCEND trial was reported in 
two articles: a UK group subset only [43], and the full multicentre study [37]. Data from the 
full study were used for all analyses where possible. 
3.1 Study characteristics 
All included articles reported on multi-centre randomised controlled trials conducted across 
more than one country. Trial size ranged from 48 to 620 participants, with five of the six 
trials having >300 participants [30, 37, 38, 44, 45]. In total, 2540 participants were enrolled 
across the six trials. Participants were those presenting with rheumatoid arthritis (n=3 trials) 
[30, 44, 45], psoriasis (n=2) [38, 46], and ankylosing spondylitis (n=1) [37, 43]. The mean age 
of participants recruited ranged from 41 to 51 years, and all trials were of mixed sex. All six 
trials were primarily safety and efficacy studies (the main clinical and safety findings being 
presented elsewhere) in participants with moderate to severe chronic disease, with 
depression being assessed as a secondary outcome measure. Only one study [38] reported 
excluding participants with psychiatric disease, and the same study also reported the 
intention to withdraw any patients who became actively suicidal during the trial. Three 
studies [30, 38, 46] reported prevalence of depression and anxiety at baseline, and the 
mood state in these populations were found to be representative of other studies of 
populations with chronic disease, ranging between 16-47% of participants showing some 
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degree of clinical depression and/or anxiety. None of the studies proactively recruited 
participants with depression. 
3.2 Intervention characteristics 
All six trials excluded anyone that had previously received TNFα inhibitor treatment. The 
three trials for participants with rheumatoid arthritis all assessed the TNFα inhibitor 
etanercept.  Etanercept was used in conjunction with methotrexate and compared against 
the standard disease modifying anti-rheumatic drug (DMARD) of choice plus methotrexate 
in two open-label RCTS [44, 45], and against methotrexate alone in the third double-blind 
RCT [30]. Trial length ranged from 16 to 52 weeks. The two trials for participants with 
psoriasis were both placebo controlled double-blind trials and assessed the effects of 
adalimumab [46] and etanercept [38] respectively. Both trials were of 12 weeks duration. 
The trial for those with ankylosing spondyitis was a 4 month long double blind study, 
reported in two articles,  comparing etanercept to sulphasalazine [37, 43].  All six trials 
found significant clinical benefit of TNFα inhibitor treatment compared to comparator 
treatment [30, 38, 44, 45, 47, 48]. 
3.3 Psychological outcome measure 
Depression was assessed as a secondary outcome in all six trials. Four of the trials used the 
Hospital Anxiety and Depression Scale (HADS) [30, 37, 43-45], one used the Zung Depression 
Scale (ZDS) [46] and one trial used two different scales: the Hamilton Rating Scale for 
Depression (HAM-D) and the Beck Depression Inventory (BDI) [38]. Anxiety was also 
assessed as a secondary outcome in four trials, with HADS as the assessment tool [30, 37, 
43-45]. 
3.4 Study Quality (risk of bias) 
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A summary of the risk of bias is presented in Figure 3. For a few trials, some of the 
information for this, where referred to and available, was taken from the ‘parent’ primary 
outcome paper [47-50] which described the trial methodology in more detail. Whilst all six 
included articles were RCTS, the studies were not without issues relating to possible bias. 
For the majority of studies, the methods of randomisation and selection of eligibility criteria 
were well described. Four of the trials were double blind and for these studies, there was 
little risk of bias with regards to blinding of participants and outcome assessments. 
However, two open-label studies were susceptible to bias of outcome measurement, but 
these limitations were recognised in both papers.  For most of the studies, outcome data 
were complete or missing data were accounted for adequately, however none of the studies 
reported on compliance with the intervention.  Data collection tools for depression and 
anxiety were all valid and reliable. All articles were presenting data that was secondary to 
the primary aim of the trial, and all articles included authors that were either employed by a 
pharmaceutical company or had received monies from pharmaceutical industry, though the 
degree to which they were involved in data interpretation and analysis was not stated for 
any of the articles.  
3.5 Effects on depression 
Data from all six trials were included in the meta-analysis on the effects of treatment on 
depression. TNFα inhibitor therapy was found to have a significant beneficial effect on 
depression across a variety of clinical populations in five of the six trials, showing small to 
medium effects. Pooling the studies together, irrespective of the depression assessment 
tool used, we found a small but statistically significant effect size of -0.24 in favour of the 
intervention group (95%CI: -0.33 to -0.14; p<0.001). The heterogeneity between studies 
(38%) was not statistically significant (p = 0.15). The forest plot for this analysis is shown in 
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Figure 4. Repeating the analysis to include only studies that reported non standardised data 
utilising the same depression assessment tool, resulted in comparable findings: the pooled 
effect of TNFα inhibitor treatment on depression in people with rheumatoid arthritis, as 
measured by HADS [30, 44, 45], resulted in an overall mean difference in HADS of -0.65 
(95%CI: -1.15 to -0.16, p=0.009) in favour of the intervention group; this equates to a pooled 
standardised mean difference of 0.16, in the three studies included in this sub-analysis.  
There was 12% heterogeneity between the three studies which was not statistically 
significant (p = 0.32).   
Two studies [38, 46] assessed whether there was an association between change in 
depression and change in clinical disease status. Menter et al. [46] found a significant 
correlation between the two, whilst Tyring et al. [38] found no strong correlation in the two 
outcomes. Neither of the studies however assessed depression frequently enough to 
determine whether the changes in depression appeared prior to changes in clinical disease 
status. None of the studies reported analysing depression in relation to inflammatory 
markers.  
3.6 Effects on anxiety 
Four studies provided data suitable for meta-analysis. Three studies were in populations 
with rheumatoid arthritis, and one in a population with ankylosing spondylitis and all used 
HADS as the assessment tool. The pooled effect of TNFα inhibitor treatment on anxiety 
resulted in an overall standardised mean difference of -0.17 in favour of the intervention 
group which was statistically significant at 5% level of significance, 95%CI: -0.31 to -0.02; p = 
0.02 (forest plot shown in Figure 5).  There was 61.7% heterogeneity between the four 
studies which was borderline statistically significant (p = 0.05).  
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4.0 Discussion 
This is the first systematic review and meta-analysis of the effects of TNFα inhibitor 
treatment on depression and anxiety in people with chronic inflammatory disease. Data 
from six randomised trials (reported in seven articles), involving a total of 2540 participants 
with moderate to severe chronic inflammatory disease, showed a small but statistically 
significant effect of TNFα inhibitor treatment on reducing depression. Although not 
measured in all studies, a significant beneficial effect of intervention was also observed for 
anxiety. The association between improvement of depression with improvement in 
inflammatory condition was inconsistent, however; one study reported an association 
between clinical improvement and improvement in depression, whereas another study 
observed no association between the two. None of the studies were able to determine 
whether the changes in depression occurred independent of, or prior to, any changes in 
markers of clinical disease activity. 
The review followed best practice guidelines for systematic reviews [34] and did not restrict 
by date or language, nor by whether studies had been published or not. Authors of papers 
who had published abstracts only, were contacted for their data, if available. Only data from 
placebo (or usual care) controlled RCTs were eligible for this review, to enable us to draw 
inferences about the causal relationship between use of TNFα inhibitors and improvements 
in depression. We pooled study findings using standardised mean differences, to enable us 
to combine findings using differing measures of depression and anxiety, but also presented 
findings for the majority of studies using the same measure using weighted mean 
difference, to aid interpretation. Importantly, the effect size of TNFα inhibitor treatment on 
depression was comparable irrespective of the meta-analytic approach taken.  
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With regards to potential weaknesses, this review included RCTs for which the primary aim 
had to been to assess safety and efficacy of treatment on physical health status. Whilst the 
designs of the included studies were robust, the primary aims of the trials were not to 
establish effects on psychological status, nor to relate this to clinical disease status and 
inflammatory biomarkers. Whilst this may be interpreted as meaning that less effort and 
rigour may have been invested in the assessments of depression, all the measures used 
were well-validated. Importantly, the self-rated assessments performed similarly to the 
observer rated HAM-D measure of depression in the one trial that used both forms of 
assessment [38], which suggests that reliance on self-rated depression measures in the 
majority of studies did not inflate the observed effects of TNFα inhibitors on depression. 
Also by focusing on secondary outcomes of trials, it could be argued that our findings are 
less likely to be influenced by publication or reporting bias. Another possible limitation for 
this review is the small number of studies that the review located. Although the trials were 
of reasonable size, and data from more than 2500 participants, was pooled for example for 
analysis of the effects  of TNFα  on depression, this does only represent six studies, and 
therefore the results need to be interpreted with caution. A further consideration must be 
given to the fact that whilst the populations included in the studies were similar on the 
grounds that they were receiving TNFα inhibitor therapy for an inflammatory condition, 
there is likely to have been considerable variation in the disease states, and the factors 
impacting on depression and anxiety of the participants within each trial, and across the 
trials of different chronic diseases. Some small reassurance is given by the three studies that 
reported baseline mood state, which were found to be representative of other studies of 
populations with chronic disease. 
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We interpret our findings as indicating that treatment with TNFα inhibitors in people with 
chronic inflammatory conditions improves depression and anxiety. The effects of TNFα 
inhibitors on depression were small, however, and whilst there is no established minimum 
clinically important difference for the HADS depression scale, the small effect observed 
would be below what most would consider to be clinically significant. Such a small effect 
could indicate that other, non- TNFα mediated mechanisms were important determinants of 
depression among the patients studied. However, a number of methodological 
characteristics of the included studies could also have influenced the size of observed effect. 
First, these small effects could be attributable, at least in-part, to the fact that the included 
studies did not specifically recruit patients with depression or anxiety (one study even 
excluded people with significant psychopathology). The prevalence of depression and 
anxiety (in the three studies where these were reported) were between 16-47%, meaning 
that the majority of patients were not depressed, thereby limiting the potential for 
antidepressant effects. Secondly, in the control arm of most of the included trials, active 
anti-inflammatory drugs (treatment as usual) were used which may have reduced the 
apparent effects of TNFα inhibitors. Effects in trials using placebo control were not 
systematically greater than those that had used active treatment however, suggesting this is 
unlikely to have influenced the findings of this review. 
Other randomised studies of TNFα inhibitor treatment in chronic disease have reported 
effects on depression of greater magnitudes to that found in this review.  Studies which 
have randomised patients with psoriasis to either paused or continuous etanercept 
treatment, or varying doses of etanercept, found 25-30% improvement in HADS depression 
scores, between a 1.5 -2.0 decrease (compared to our mean effect difference in our review 
of 0.65) [51, 52]. Whist the intervention groups in the RCTs in our present review also saw 
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decreases in depression of similar magnitude (i.e. of  between 1.0-3.0 in HADS depression 
score), depression scores in the control groups in our included studies were also found to 
improve, albeit by less, hence the lower overall mean effect difference. Loftus, in their study 
randomising individuals to different doses of adalimumab for Crohn’s disease, found a 
significant reduction in depression (9 points on the ZDS), slightly higher than that reported 
in the study by Menter et al., included within this review [53]. Of interest, the regimes used 
in these dosing studies were comparable and/or higher to those used in the studies in this 
present review, however none of them observed greater responses with the higher doses. 
Whilst these trials comparing different doses of the TNFα inhibitors were excluded by our a 
priori criteria, their findings are in agreement with a small but significant effect of TNFα 
inhibitors on depression.  
Whilst our review provides evidences that treatment with TNFα inhibitors improves 
depression, it fails to indicate whether the mechanisms of improving depression are directly 
mediated by a reduction in TNFα or whether the benefits to depression are secondary to 
reductions in pain and disability associated with improvement in chronic inflammatory 
condition. None of the included studies provided sufficient detail of the timing of changes in 
depression relative to the changes in clinical disease status to determine whether 
improvements in mood predate improvements in markers of clinical status. In the study by 
Tyring et al. [38], there was a lack of a strong correlation between the improvements in 
depression and in markers of clinical disease status, which led the authors to conclude that 
treatment affected depression directly (i.e. not secondary to improvements in clinical 
status).  
Raison et al. [54] have recently considered the mechanism of effect of TNFα inhibitors on 
depression in the first published RCT of TNFα inhibitor therapy (infliximab) for individuals 
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with treatment resistant depression. They found that Infliximab had no overall effect on 
depression in the sample as a whole. Whilst individuals with diagnosed autoimmune 
disorders were excluded, the authors did find reductions in depression among subjects with 
higher baseline levels of inflammation (hs-CRP>5mg/L). In addition to this, a case study of 
TNFα inhibitor therapy (infliximab) for five individuals with late onset depressive disorder, 
found no effect on depression in four individuals, but complete disappearance of depressive 
symptoms in the only patient with a comorbid inflammatory condition [55]. The findings of 
both of these studies are consistent with the conclusion that TNFα inhibitors improve 
depression directly via inflammatory pathways, though both fall short of proving this 
mechanism of effect.  
Future research needs to take the extant findings and start to tease out the some of the 
unknown issues highlighted. For example, would anti-inflammatory treatment benefit 
certain subgroups of populations with depression who present with elevated inflammatory 
biomarkers. As such, might existing levels of TNFa in individuals with depression indicate 
who is likely to respond to anti-inflammatory therapy, or might some other inflammatory 
biomarker be more appropriate. In terms of trying to tease out cause and effect, is it 
possible with more detailed investigations into the timeline of changes to both clinical 
indicators of disease and biomarkers of inflammatory status to see how inflammation 
impacts depression and anxiety.  
Conclusion 
In summary, TNFα inhibitor therapy reduces depression and anxiety in people with chronic 
disease. Whilst this is consistent with a proposed inflammatory mechanism of depression, 
further studies are require to establish the mechanism of effect, by investigating a more 
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detailed timeline of changes in depression, clinical markers of disease activity status and 
inflammatory biomarkers, and the extent to which improvements in depression correlate 
with improvements in clinical and inflammatory status. 
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Table 1.  Study characteristics and summary of main depression and anxiety outcome data 
Author Location Population (including 
prevalence of depression 
& anxiety) 
 
Intervention  Depression & 
anxiety measure 
 Findings (Intervention vs Comparator) 
 
Bae 2013 
APPEAL 
study 
Multi (Hong 
Kong, India, 
Malaysia, 
Philippines, 
Taiwan, Korea 
and Thailand) 
300 adults with 
rheumatoid arthritis (who 
showed inadequate 
response to oral MTX), 
mean age 48yrs  
 
Baseline depression 
prevalence not reported 
 
Open-label study.  
ETN (25mg 2/week) + 
MTX (n=197)  vs  
DMARD + MTX 
(N=103) for 16 weeks 
HADS Depression improvement:  
7.62 to 5.42 (-28.7% ) for ETN vs 7.85 to 6.56 (-
16.4%) for DMARD, p=0.016 
 
Anxiety improvement:  
29.1%(ETN) vs 18.5% (DMARD) improvement, 
p=0.026 
 
Kekow 2010 
COMET 
study 
 
Multi (Europe, 
Latin America, 
Asia, Australia) 
528 adults with early 
active rheumatoid arthritis, 
mean age 51yrs 
 
Baseline depression: 47% 
Baseline anxiety: 37% 
 
Double blind study.  
ETN (50mg 1/week) + 
MTX (n= 265)  vs 
MTX (n=263) for 52 
weeks 
HADS Depression no significant change:  
6.82 to 4.39 (-2.43) for ETN vs 6.68 to 4.66 (-2.02) 
for MTX, Not Significant (NS)  
 
Anxiety no change:  
-2.12(ETN) vs -1.92 (MTX) improvement, NS 
 
Machado 
2014 
Multi (Argentina, 
Chile, Columbia, 
Mexico, Panama) 
429 adults with 
rheumatoid arthritis (who 
showed inadequate 
response to MTX), mean 
age 48yrs 
 
Baseline depression 
prevalence not reported 
 
Open label study.  
ETN (50mg 1/week) + 
MTX (n=284)  vs 
DMARD + MTX 
(n=145) for 24 weeks 
HADS Depression improvement:  
adjusted mean change: -2.8 (0.2) for ETN vs -1.9 
(0.3) for DMARD, p=0.0077 
 
Anxiety no change:  
-2.2(0.3) for ETN vs -1.7 (0.3) for DMARD, p=0.16 
Menter 2010 Multi (USA and 
Canada) 
97 adults with psoriasis, 
mean age 44yrs 
 
Baseline depression: 35% 
Double blind study. 
ADM (40mg 1/week) 
(n=45)  vs Placebo 
(n=52) for 12 weeks 
ZDS Depression improvement:  
42.9 (12.4) to 36.2 (11.5) for ADAL vs 45.8 (14.0) to 
44.2 (14.2) for placebo,  
Difference  in change -6.0 (-9.5 to -2.5), p=0.001   
 
(Improvement in ZDS correlated with improvement in 
physical symptoms (r=0.5, p<0.001), but not able to 
assess which came first)  
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Packham 
2012 
ASCEND 
study ** 
Multi (centres 
across the UK) 
Subgroup of 48 adults with 
ankylosing spondylitis in 
UK, mean age 41yrs 
 
Baseline depression 
prevalence not reported 
Double blind study. 
ETN (50mg 1/week) 
(n=29) vs SLZ 
(n=19) for 16 weeks 
HADS Depression improvement:  
effect size (ES) greater for ETN, n=29, (ES – 0.86) 
compared to SSZ, n=15 (ES – 0.39), no statistics 
presented 
 
Anxiety no change:  
ES similar between 0.68 (ETN) vs 0.81 (SSZ), no 
statistics presented 
 
Tyring 2006 Multi (USA and 
Canada) 
620 adults with psoriasis, 
mean age 46yrs 
 
Baseline depression: 19% 
mild, 15% moderate 
(BDI); 24% mild, 2% 
moderate (HAM-D) 
   
Double blind study. 
ETN (25mg 2/week) 
(n=311) vs Placebo 
(n=309) for 12 weeks 
 
HAM-D and BDI  Depression:  
i) HAM-D Depression improvement  
ETN vs Placebo, 1.5 vs 0.4, (CI 0.4-1.9, p=0.0012), 
ES of 0.25   
2) BDI Depression Improvement 
ETN vs Placebo, 1.8, (CI 0.6-2.9, p<0.001), ES of 
0.22.   
 
(Changes in depression not strongly correlated with 
objective clinical measures.) 
  
Van der 
Heijde 2012 
ASCEND 
study ** 
 
Multi (Europe, 
Latin America, 
Asia, Australia) 
566 adults wit 
ankylosing spondylitis, 
mean age 41yrs 
 
Baseline depression 
prevalence not reported 
Double blind study. 
ETN (50mg 1/week) 
(n= 379) vs SSZ (n= 
187) for 16 weeks 
HADS   Depression improvement:  
Greater improvement in ETN vs SSZ: -0.7 (3.0), p 
<0.05   
 
Anxiety improvement:   
Greater improvement in ETN vs SSZ: -0.6 (3.0) , p 
<0.05   
 
** same study 
Drug: Assessment tools: 
ADM - Adalimumab 
DMARD – Disease modifying anti rheumatic drug 
ETN – Etanercept 
MTX – Methotrexate 
SSZ - Sulphsalazine 
 
BDI – Beck Depression Inventory 
HADS – Hospital Anxiety and Depression Scale 
HAM-D  Hamilton’s Rating Scale for Depression 
ZDS – Zung’s self-rating  Depression Scale  
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Legends for Figures 
 
Figure 1:  Example of search strategy used on Medline. 
 
Figure 2:  PRISMA flow diagram showing identification of included studies. 
 
Figure 3:  Cochrane risk of bias table of included studies. 
 
Figure 4:  Forest plot showing the results of the meta-analysis on the effects of TNFa 
inhibitor treatment on depression. 
 
Figure 5:  Forest plot showing the results of the meta-analysis on the effects of TNFa 
inhibitor treatment on anxiety. 
 
 
